Global Aptamers Market

Aptamers Market Size, Share, Growth Analysis, By Type(Nucleic Acid and Peptide), By Application(Diagnostics, Therapeutics, Research & Development, Others), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35E2038 | Region: Global | Published Date: September, 2024
Pages: 219 | Tables: 62 | Figures: 77

Aptamers Market Regional Insights

With a market share of 44.48% in 2023, North America region led the aptamers market. The rising incidence of chronic diseases, the region's robust healthcare system, and the growing interest of research labs in the field of aptamers are some of the main drivers of the area's supremacy. Also in April 2022, Noxxon Pharma made the announcement that it would disclose top line results for its NOX-A12 GLORIA study in brain cancer at the annual meeting of the American Society of Clinical Oncology.

The market for aptamers in Asia Pacific is anticipated to expand at the quickest rate, with a CAGR of 26.18%. The region's growth is attributable to the acceptance of new aptamer-based products in the area. For instance, Achiko AG signed a contract with the Pengurus Wilayah Nahdlatul Ulama DKI, the largest Islamic organization in the world with headquarters in Jakarta, for the marketing and distribution of Aptamer, a COVID-19 diagnostic kit based on aptamers. In Indonesia, this organization has 90 million registered members.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Aptamers Market size was valued at USD 155 million in 2022 and is poised to grow from USD 182.59 million in 2023 to USD 677.08 million by 2031, growing at a CAGR of 17.80% during the forecast period (2024-2031).

To increase their market share, major players are using tactics including product modification, new product approval, mergers and acquisitions, and geographical growth. These methods are all aimed at improving their current products. Applications of aptamers in therapeutics may find new growth opportunities as a result of such activities. 'Aptamer Group (UK) ', 'Raptamer Discovery Group (US) ', 'Somalogic, Inc. (US) ', 'Aptamer Sciences, Inc. (US) ', 'Aptagen, LLC  (US) ', 'Maravai Lifesciences (US) ', 'Kaneka Corporation (Japan) ', 'NeoVentures Biotechnology Inc. (Canada) ', 'Aptus Biotech (Spain) ', 'Base Pair Biotechnologies (US) ', 'Amsbio (UK) ', 'Novaptech (France) ', 'Bio-Techne (US) ', 'Aptitude Medical Systems (US) ', 'Raybiotech, Inc. (US) ', 'Alpha Diagnostic International, Inc. (US) ', 'Creative Biolabs (US) ', 'Creative Biogene (US) ', 'Vivonics Inc. (US) ', 'Iba Lifesciences GmbH (Germany) ', 'Aptabharat Innovations Pvt. Ltd (India) ', 'Profacgen (US) ', 'Mediven (Germany) ', 'Pure Biologics SA (Poland) ', 'Oak Biosciences, Inc. (US)'

Aptamers play a crucial role in personalized medicine as they can specifically bind to target molecules, including proteins, peptides, and small molecules. The growing emphasis on targeted therapies and precision medicine has led to increased demand for aptamers as they offer advantages such as high specificity, low immunogenicity, and customizable properties. Aptamers enable precise molecular recognition, facilitating the development of personalized treatment strategies.

Focus on SELEX Optimization and Automation : SELEX (Systematic Evolution of Ligands by Exponential Enrichment) is the primary method for aptamer selection. There is a growing focus on optimizing and automating the SELEX process to enhance efficiency, reduce costs, and improve aptamer quality. Advances in high-throughput screening, microfluidics, and robotics are being employed to streamline the aptamer development process, making it more accessible and scalable.

With a market share of 44.48% in 2023, North America region led the aptamers market. The rising incidence of chronic diseases, the region's robust healthcare system, and the growing interest of research labs in the field of aptamers are some of the main drivers of the area's supremacy. Also in April 2022, Noxxon Pharma made the announcement that it would disclose top line results for its NOX-A12 GLORIA study in brain cancer at the annual meeting of the American Society of Clinical Oncology.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Primer Market
Buy Now GET FREE SAMPLE
OKR Software Market
Buy Now GET FREE SAMPLE
Trocars Market
Buy Now GET FREE SAMPLE
Esterquats Market
Buy Now GET FREE SAMPLE
Intellectual Property Management Software Market
Buy Now GET FREE SAMPLE
Healthcare Payer Services Market
Buy Now GET FREE SAMPLE
Dental Burs Market
Buy Now GET FREE SAMPLE
Biopolymers Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Aptamers Market

Report ID: SQMIG35E2038

$5,300
BUY NOW GET FREE SAMPLE